|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DTX3L |
Gene summary for DTX3L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DTX3L | Gene ID | 151636 |
| Gene name | deltex E3 ubiquitin ligase 3L | |
| Gene Alias | BBAP | |
| Cytomap | 3q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | Q8TDB6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 151636 | DTX3L | HTA11_347_2000001011 | Human | Colorectum | AD | 3.69e-10 | 3.15e-01 | -0.1954 |
| 151636 | DTX3L | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.97e-10 | 3.84e-01 | -0.059 |
| 151636 | DTX3L | HTA11_99999970781_79442 | Human | Colorectum | MSS | 8.75e-10 | 3.67e-01 | 0.294 |
| 151636 | DTX3L | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.43e-04 | 7.68e-01 | 0.3487 |
| 151636 | DTX3L | HTA11_99999971662_82457 | Human | Colorectum | MSS | 7.51e-03 | 2.04e-01 | 0.3859 |
| 151636 | DTX3L | LZE2T | Human | Esophagus | ESCC | 2.66e-05 | 5.04e-01 | 0.082 |
| 151636 | DTX3L | LZE4T | Human | Esophagus | ESCC | 6.17e-12 | 4.16e-01 | 0.0811 |
| 151636 | DTX3L | LZE5T | Human | Esophagus | ESCC | 1.07e-03 | 1.94e-01 | 0.0514 |
| 151636 | DTX3L | LZE7T | Human | Esophagus | ESCC | 2.00e-02 | 1.91e-01 | 0.0667 |
| 151636 | DTX3L | LZE8T | Human | Esophagus | ESCC | 2.31e-11 | 2.99e-01 | 0.067 |
| 151636 | DTX3L | LZE20T | Human | Esophagus | ESCC | 5.58e-05 | 1.93e-01 | 0.0662 |
| 151636 | DTX3L | LZE22T | Human | Esophagus | ESCC | 1.42e-04 | 3.05e-01 | 0.068 |
| 151636 | DTX3L | LZE24T | Human | Esophagus | ESCC | 8.89e-32 | 7.58e-01 | 0.0596 |
| 151636 | DTX3L | LZE6T | Human | Esophagus | ESCC | 5.75e-03 | 1.78e-01 | 0.0845 |
| 151636 | DTX3L | P1T-E | Human | Esophagus | ESCC | 2.67e-14 | 6.26e-01 | 0.0875 |
| 151636 | DTX3L | P2T-E | Human | Esophagus | ESCC | 2.24e-24 | 5.20e-01 | 0.1177 |
| 151636 | DTX3L | P4T-E | Human | Esophagus | ESCC | 1.37e-12 | 2.09e-01 | 0.1323 |
| 151636 | DTX3L | P5T-E | Human | Esophagus | ESCC | 6.67e-17 | 3.54e-01 | 0.1327 |
| 151636 | DTX3L | P8T-E | Human | Esophagus | ESCC | 1.87e-44 | 8.31e-01 | 0.0889 |
| 151636 | DTX3L | P9T-E | Human | Esophagus | ESCC | 1.34e-33 | 7.42e-01 | 0.1131 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003133128 | Skin | cSCC | positive regulation of cellular catabolic process | 182/4864 | 427/18723 | 3.29e-14 | 2.22e-12 | 182 |
| GO:190382928 | Skin | cSCC | positive regulation of cellular protein localization | 129/4864 | 276/18723 | 6.43e-14 | 4.09e-12 | 129 |
| GO:005109827 | Skin | cSCC | regulation of binding | 152/4864 | 363/18723 | 2.21e-11 | 1.10e-09 | 152 |
| GO:000961522 | Skin | cSCC | response to virus | 152/4864 | 367/18723 | 5.88e-11 | 2.75e-09 | 152 |
| GO:007093623 | Skin | cSCC | protein K48-linked ubiquitination | 41/4864 | 65/18723 | 3.34e-10 | 1.37e-08 | 41 |
| GO:190018022 | Skin | cSCC | regulation of protein localization to nucleus | 69/4864 | 136/18723 | 5.37e-10 | 2.14e-08 | 69 |
| GO:001657024 | Skin | cSCC | histone modification | 179/4864 | 463/18723 | 9.65e-10 | 3.74e-08 | 179 |
| GO:190018219 | Skin | cSCC | positive regulation of protein localization to nucleus | 49/4864 | 87/18723 | 1.84e-09 | 6.73e-08 | 49 |
| GO:000020924 | Skin | cSCC | protein polyubiquitination | 103/4864 | 236/18723 | 2.57e-09 | 9.09e-08 | 103 |
| GO:000703419 | Skin | cSCC | vacuolar transport | 74/4864 | 157/18723 | 8.60e-09 | 2.72e-07 | 74 |
| GO:003139729 | Skin | cSCC | negative regulation of protein ubiquitination | 45/4864 | 83/18723 | 4.04e-08 | 1.05e-06 | 45 |
| GO:190332129 | Skin | cSCC | negative regulation of protein modification by small protein conjugation or removal | 49/4864 | 95/18723 | 8.44e-08 | 2.04e-06 | 49 |
| GO:00516076 | Skin | cSCC | defense response to virus | 107/4864 | 265/18723 | 1.84e-07 | 4.02e-06 | 107 |
| GO:01405466 | Skin | cSCC | defense response to symbiont | 107/4864 | 265/18723 | 1.84e-07 | 4.02e-06 | 107 |
| GO:005105217 | Skin | cSCC | regulation of DNA metabolic process | 136/4864 | 359/18723 | 3.83e-07 | 7.58e-06 | 136 |
| GO:005109927 | Skin | cSCC | positive regulation of binding | 74/4864 | 173/18723 | 1.09e-06 | 1.93e-05 | 74 |
| GO:00335235 | Skin | cSCC | histone H2B ubiquitination | 11/4864 | 12/18723 | 3.30e-06 | 5.08e-05 | 11 |
| GO:001657415 | Skin | cSCC | histone ubiquitination | 27/4864 | 47/18723 | 4.79e-06 | 7.03e-05 | 27 |
| GO:2001020111 | Skin | cSCC | regulation of response to DNA damage stimulus | 87/4864 | 219/18723 | 5.38e-06 | 7.75e-05 | 87 |
| GO:004339325 | Skin | cSCC | regulation of protein binding | 79/4864 | 196/18723 | 7.59e-06 | 1.04e-04 | 79 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa043306 | Esophagus | ESCC | Notch signaling pathway | 42/4205 | 62/8465 | 2.97e-03 | 7.97e-03 | 4.08e-03 | 42 |
| hsa0433013 | Esophagus | ESCC | Notch signaling pathway | 42/4205 | 62/8465 | 2.97e-03 | 7.97e-03 | 4.08e-03 | 42 |
| hsa043305 | Oral cavity | OSCC | Notch signaling pathway | 44/3704 | 62/8465 | 1.26e-05 | 5.55e-05 | 2.83e-05 | 44 |
| hsa0433012 | Oral cavity | OSCC | Notch signaling pathway | 44/3704 | 62/8465 | 1.26e-05 | 5.55e-05 | 2.83e-05 | 44 |
| hsa0433021 | Oral cavity | NEOLP | Notch signaling pathway | 21/1112 | 62/8465 | 2.23e-05 | 1.87e-04 | 1.18e-04 | 21 |
| hsa0433031 | Oral cavity | NEOLP | Notch signaling pathway | 21/1112 | 62/8465 | 2.23e-05 | 1.87e-04 | 1.18e-04 | 21 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DTX3L | SNV | Missense_Mutation | novel | c.552N>G | p.Ile184Met | p.I184M | Q8TDB6 | protein_coding | deleterious(0) | possibly_damaging(0.808) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DTX3L | SNV | Missense_Mutation | rs762198657 | c.779N>T | p.Arg260Ile | p.R260I | Q8TDB6 | protein_coding | deleterious(0.01) | possibly_damaging(0.548) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DTX3L | SNV | Missense_Mutation | novel | c.564G>C | p.Leu188Phe | p.L188F | Q8TDB6 | protein_coding | tolerated(0.09) | benign(0.065) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
| DTX3L | SNV | Missense_Mutation | rs376434730 | c.1018N>A | p.Glu340Lys | p.E340K | Q8TDB6 | protein_coding | tolerated(0.64) | benign(0.006) | TCGA-AR-A255-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD |
| DTX3L | SNV | Missense_Mutation | c.325N>A | p.Ala109Thr | p.A109T | Q8TDB6 | protein_coding | tolerated(0.51) | benign(0.015) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| DTX3L | insertion | In_Frame_Ins | novel | c.2146_2147insGAATGT | p.Pro716delinsArgMetSer | p.P716delinsRMS | Q8TDB6 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| DTX3L | insertion | Frame_Shift_Ins | novel | c.2147_2148insTTCATTGGCTGGAA | p.Glu717SerfsTer16 | p.E717Sfs*16 | Q8TDB6 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| DTX3L | insertion | Frame_Shift_Ins | novel | c.597_598insATAAAAC | p.Gln200IlefsTer27 | p.Q200Ifs*27 | Q8TDB6 | protein_coding | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| DTX3L | insertion | Nonsense_Mutation | novel | c.1347_1348insGGGCATACATAACCACACTGTGCCCTAGTATC | p.Arg450GlyfsTer4 | p.R450Gfs*4 | Q8TDB6 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
| DTX3L | SNV | Missense_Mutation | novel | c.544N>C | p.Glu182Gln | p.E182Q | Q8TDB6 | protein_coding | deleterious(0.01) | benign(0.352) | TCGA-C5-A1M7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |